1800-272-662
Shopping Cart 0
countryflagAU
Login

Firebrick Pharma Ltd

Healthcare AU FRE

0.055AUD
-0.003(5.17%)

Last update at 2026-03-13T03:33:00Z

Day Range

0.060.06
LowHigh

52 Week Range

0.050.10
LowHigh

Fundamentals

  • Previous Close 0.06
  • Market Cap13.89M
  • Volume27500
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.36997M
  • Revenue TTM0.41M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM 0.19M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -2.63443M -1.17586M -6.80207M -3.79631M -2.43904M
Minority interest - - - - -
Net income -2.63443M -1.17586M -6.80207M -3.79631M -2.43904M
Selling general administrative 0.30M 0.22M 2.76M 0.50M 1.73M
Selling and marketing expenses 0.74M 0.26M - 0.33M -
Gross profit 0.10M -0.02278M 0.00083M 0.00412M -
Reconciled depreciation 0.00862M 0.00718M 0.00952M 0.00694M -
Ebit -2.86569M -1.17486M -6.75187M -3.79217M -2.43980M
Ebitda -2.85708M -1.16768M -6.85422M -3.78523M -
Depreciation and amortization 0.00862M 0.00718M - 0.00694M -
Non operating income net other - - - - -
Operating income -2.86569M -3.92762M -6.86374M -3.79217M -2.86180M
Other operating expenses 3.16M 3.94M 0.19M 4.88M 0.07M
Interest expense 0.00918M 0.00101M - 0.00414M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.00918M 0.02M 0.04M 0.00128M 0.00076M
Net interest income 0.00918M 0.02M 0.04M -0.00286M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.22209M -2.73578M - 1.08M -
Total revenue 0.29M 0.01M 0.00083M 0.00412M 0.00000M
Total operating expenses 2.97M 3.90M - 4.88M -
Cost of revenue 0.19M 0.04M - - -
Total other income expense net 0.23M 2.75M 0.02M 1.08M -
Discontinued operations - - - - -
Net income from continuing ops -2.63443M -1.17586M -6.80207M -3.79631M -
Net income applicable to common shares -2.63443M -1.17586M -6.80207M -3.79631M -2.43904M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 1.83M 2.41M 2.98M 8.73M 11.77M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.05M 0.08M 0.10M 0.00535M 0.01M
Total liab 0.27M 0.29M 0.51M 0.45M 0.21M
Total stockholder equity 1.56M 2.12M 2.48M 8.28M 11.55M
Deferred long term liab - - - - -
Other current liab - 0.22M 0.17M 0.41M 0.08M
Common stock - 17.88M 17.07M 16.00M 15.99M
Capital stock 19.90M - 17.07M 16.00M 15.99M
Retained earnings -18.78725M -16.51202M -15.57866M -8.80510M -5.23911M
Other liab - - - - -
Good will - - - - -
Other assets - 0.00000M 0.36M 0.36M 0.08M
Cash 0.98M 0.82M 2.35M 7.14M 10.88M
Cash and equivalents - - - - -
Total current liabilities 0.27M 0.29M 0.51M 0.45M 0.21M
Current deferred revenue - - - - -
Net debt - -0.82478M - -7.14290M -10.87588M
Short term debt - - 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - - 0.99M 1.08M 0.81M
Property plant equipment - - 0.03M 0.04M 0.02M
Total current assets 1.48M 2.09M 2.59M 8.33M 11.68M
Long term investments - - - - -
Net tangible assets - - 2.48M 8.28M 1.55M
Short term investments - - - - 0.28M
Net receivables 0.01M 0.95M 0.14M 1.08M 0.50M
Long term debt - - - - -
Inventory 0.19M 0.24M - 0.10M -
Accounts payable 0.11M 0.07M 0.20M 0.04M 0.14M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.74M - 1.08M 0.81M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.25M 0.29M 0.36M 0.36M 0.08M
Deferred long term asset charges - - - - -
Non current assets total 0.34M 0.31M 0.39M 0.40M 0.09M
Capital lease obligations - - - - -
Long term debt total - - 0.00000M 0.00000M 0.00000M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.08298M -0.00013M -0.00162M -0.03254M -
Change to liabilities - - 0.06M 0.20M -0.07110M
Total cashflows from investing activities -0.08298M -0.00013M -0.00162M -0.03254M -0.01607M
Net borrowings - - - - -
Total cash from financing activities 2.02M 0.82M 1.00M 10.23M 3.01M
Change to operating activities - - 0.00711M -0.05015M -0.01275M
Net income -2.63443M -1.17586M -6.80207M -3.79631M -2.43904M
Change in cash 0.16M -1.52980M -4.78832M 5.99M 1.06M
Begin period cash flow 0.82M 2.35M 7.14M 1.15M -
End period cash flow 0.98M 0.82M 2.35M 7.14M 1.15M
Total cash from operating activities -1.77920M -2.34488M -5.78336M -4.20223M -1.93610M
Issuance of capital stock 1.93M 0.82M 1.00M 10.70M -
Depreciation - 0.00718M 0.00952M 0.00694M 0.00052M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory 0.03M -0.16780M - -0.28324M -0.28324M
Change to account receivables 0.69M -0.81360M 0.94M -0.57849M 0.05M
Sale purchase of stock -0.02739M -0.00529M 1.00M -0.47408M 3.13M
Other cashflows from financing activities 0.12M -0.00013M -0.00626M 0.11M -0.11637M
Change to netincome - - 0.00211M 0.30M 0.53M
Capital expenditures 0.08M 0.00013M 0.00162M 0.03M 0.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.78M -1.17610M -4.25429M -2.80772M -1.53630M
Stock based compensation - -0.00009M - - -
Other non cash items -2.56414M -0.24045M - - -
Free cash flow -1.86218M -2.34501M -5.78497M -0.03254M -

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
FRE
Firebrick Pharma Ltd		 -0.003 5.17% 0.06 - - 33.81 7.55 41.01 -8.0904

Reports Covered

Stock Research & News

View All

Profile

Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.

Firebrick Pharma Ltd

440 Collins Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Dr. Peter Laurence Molloy BSc, FAICD, MBA Founder, Exec. Chairman & CEO 1954
Dr. Stephen Francis Goodall MASc, MBA Founder, COO & Exec. Director NA
Mr. Kavi Bekarma B.Sc., C.A. Chief Financial Officer NA
Dr. Simon Tucker Chief Scientific Officer NA
Ms. Robyn Branigan Head of Marketing NA
Prof. Peter Friedland Chief Medical Officer NA
Dr. Monique Baldwin Head of Regulatory Affairs NA
Ms. Kyla Garic Exec. Officer NA
Mr. Stephen Buckley Company Sec. NA
Dr. Peter Laurence Molloy BSc, FAICD, MBA Founder, Executive Chairman & CEO 1954

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.